Compare HOFT & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOFT | HURA |
|---|---|---|
| Founded | 1924 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 160.5M |
| IPO Year | 1999 | N/A |
| Metric | HOFT | HURA |
|---|---|---|
| Price | $13.99 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 58.3K | ★ 327.9K |
| Earning Date | 04-16-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $138.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.62 | $0.41 |
| 52 Week High | $18.09 | $3.90 |
| Indicator | HOFT | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 37.88 |
| Support Level | $11.99 | $1.82 |
| Resistance Level | $15.97 | $2.20 |
| Average True Range (ATR) | 0.80 | 0.14 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 26.60 | 1.32 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.